Back to today’s briefing

Story perspectives

Quincy Unveils Fast-Acting Nasal Spray for Depression

3/30/2025

48 8

Summary

Story summary

In Quincy, Blessing Health System introduces an innovative solution for Treatment-Resistant Depression (TRD) with esketamine, known as Spravato. This FDA-approved nasal spray, used in conjunction with oral antidepressants, promises rapid relief from symptoms, often within hours. Patients receive careful monitoring during bi-weekly treatments, though it's not recommended for pregnant women or those with specific mental health issues.

1 of 1

Story summary

In Quincy, Blessing Health System introduces an innovative solution for Treatment-Resistant Depression (TRD) with esketamine, known as Spravato. This FDA-approved nasal spray, used in conjunction with oral antidepressants, promises rapid relief from symptoms, often within hours. Patients receive careful monitoring during bi-weekly treatments, though it's not recommended for pregnant women or those with specific mental health issues.